Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA recalls more than 7,000 bottles of antidepressant
FDA recalls more than 7,000 bottles of antidepressant over a possible cancerous chemical
The FDA is recalling more than 7,000 bottles of the antidepressant duloxetine due to a possible cancer-causing chemical.
FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine: Here’s Why
The U.S. Food and Drug Administration has recalled thousands of bottles of the antidepressant Duloxetine for potentially cancer-causing chemicals in the medication.
FDA issues recall for antidepressant drug
The Federal Drug Administration issued a recall on Tuesday for a common medicine for depression. Over 7,000 bottles of Duloxetine were recalled due to the elevated presence of Nitrosamine, an ingredient believed to be cancerous,
FDA, RSV and Pfizer
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
Pfizer announces FDA approval of Abrysvo
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of
FDA, Novo Nordisk
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
17h
on MSN
FDA and CBP Seize $76 Million in Illegal Vapes From China
Roughly 3 million units were confiscated in the operation as part of a federal crackdown on illegal e-cigarettes.
1d
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...
BioSpace
19h
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
4h
I Participated in the First FDA-Approved Stem Cell Trial for MS. It Changed My Life.
Robbin Gordon-Cartier was diagnosed with multiple sclerosis in 2011. Then, she was asked to participate in a stem cell trial ...
20h
on MSN
Dog Medicine Recall Update As FDA Sets Risk Class
A class II risk level is given to products that "may cause temporary or medically reversible adverse health consequences." ...
Managed Healthcare Executive
15h
FDA Approves Stelara Biosimilar Selardsi for Additional Indications
This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.
17h
FDA Appoints New Head of Medical Devices
Diane Zuckerman is president of the National Center for Health Research, a nonprofit that monitors FDA device policy. Speaking to the Times, she said she said Tarver is focused on patient safety and ...
22h
FDA grants marketing authorisation to Peytant’s AMStent system
Peytant Solutions has received marketing authorisation from the US Food and Drug Administration (FDA) for its AMStent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Food and Drug Administration
recall
Pfizer
Novo Nordisk
Ozempic
Feedback